Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Immuneering Corporation (NASDAQ:IMRX) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $17.5714.

IMRX has been the subject of several recent research reports. Needham & Company LLC increased their price objective on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Immuneering in a research note on Tuesday, May 19th. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Finally, Cantor Fitzgerald assumed coverage on Immuneering in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target for the company.

Immuneering Stock Performance

Immuneering stock opened at $4.32 on Friday. Immuneering has a twelve month low of $2.90 and a twelve month high of $10.08. The firm has a market cap of $279.50 million, a PE ratio of -3.69 and a beta of 0.41. The firm’s 50 day moving average price is $4.75 and its two-hundred day moving average price is $5.05.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. Equities analysts anticipate that Immuneering will post -1.09 EPS for the current fiscal year.

Institutional Trading of Immuneering

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Immuneering by 2.0% in the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after purchasing an additional 4,458 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Immuneering during the fourth quarter valued at about $33,000. Southport Management L.L.C. lifted its position in shares of Immuneering by 1.8% in the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after buying an additional 5,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after buying an additional 6,196 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Immuneering by 30.0% during the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock worth $192,000 after acquiring an additional 6,725 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.